Redeye considers Arise’s Q2 2024 report to be solid, where the reported EBITDA was completely in lin...
Consti reports its Q2 results on Friday 19th of July.
- EBIT SEK 131m (-11% vs. ABGSCe, -4% vs. FactSet cons) - We expect consensus EBIT to come down by 2...
- Sales -2% vs. cons, adj. EBIT -19% vs. cons - Utilisation up due to reduction of unstaffed FTEs - ...
- Q2 sales impacted by lower Public DK deliveries – again - We cut '24e-'26e EBIT by 12-5% on lower ...
- Beat on Q2 sales (+3%) and EBITDA (+24%) vs ABGSCe - EBITDA up 2% for '24e and 1% for '25e - Our c...
- Order intake growth driven by sports & outdoor clients - We raise '24e-'26e sales by 2-1% and EBIT...
- Q2e: sales +41% y-o-y (0% excl. SDR), ~9% EBIT margin - Lifting '24e EPS by 41% on a DKK 135m Q2e ...
Aixia nästan tredubblar nettoomsättningen i det andra kvartalet och fortsätter att skörda framgångar...
AlzeCure Pharma fortsätter alltjämt att generera data för sina projekt har bland annat presenterat n...
Redeye comments on the latest readout from the trial of tasquinimod in multiple myeloma.
- Sales +9% and EBIT +11% vs. ABGSCe - Organic growth of +14%, better than ABGSCe +5% - Likely to se...
SRV reports its Q2 results on Thursday 18th of July.
Redeye lowered its Base Case and forecasts somewhat following a Q2 report on the somewhat soft side,...
- Q2 in line with ABGSCe but softer outlook for Q3 - We cut adj.
Plejds nettoomsättning för det andra kvartalet 2024 uppgick till 146,2 MSEK (110,3), en ökning med 3...
Redeye provides a more in-depth review of Episurf Medical’s Q2 report.
- Q2e: lower top-line y-o-y, but strong GM supports EBIT - EBIT down 5-4% on slower assumed market r...
Ahead of the Fiskars Q2, due on 18 July, we maintain our estimates intact.
Redeye recognizes that volatile sales over quarters are currently an issue for the share performance...
